Yorvipath (palopegteriparatide) — Blue Cross Blue Shield of New Mexico
Other FDA labeled or compendia-supported indications
Initial criteria
- Member resides in Ohio AND plan is Fully Insured or HIM Shop (SG)
- No FDA-labeled contraindications
- Has another FDA labeled indication for agent and route OR indication supported in compendia OR prescriber submitted two peer-reviewed journal articles supporting proposed use
Approval duration
12–36 months (BCBSOK 36 months; others 12 months)